ICE Bioscience

Excited to share that we’re expanding our Antibody-Drug Conjugate (ADC) services to offer even more comprehensive solutions for our partners! 👉https://lnkd.in/gEWvG7J4 From innovative payload screening and in-depth bystander effect assays to advanced in vivo models, we’re here to support every step of your ADC journey. With our extensive experience and tailored approach, we help turn groundbreaking science into real-world therapies. Let's innovate together and take ADC discovery to the next level! #ADC #Biotech #payload #DMPK #bystandereffect #DrugDevelopment #invivo #invitro

ICE Bioscience will be showcasing three posters at the AAPS PharmSci 360 2024, taking place from October 20-23 in Salt Lake City, UT. Our posters focus on innovative drug discovery and screening solutions, and will be presented by Dr. Fujun Zhang and Dr. Xiao Guo: ☑️ T1030-04-21: A PARPi Screening Cascade to Facilitate Novel Drug Discovery ☑️ M1030-04-19: Integrated Screening Platform of PDE for Lung Fibrosis Drug Discovery ☑️ M1230-04-24: Screening of CDK Inhibitors in Breast Cancer Looking forward to engaging with fellow experts and industry leaders! #AAPSPharmSci360 #DrugDiscovery #PharmaceuticalScience #OncologyResearch #LungFibrosis #PARPInhibitors #CDKInhibitors #ScientificPosters #AAPS

We will be exhibiting at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, taking place from October 23-25, 2024, at the CCIB in Barcelona, Spain. We invite all attendees to stop by Booth 13 to learn more about our cancer research solutions. Don't miss this opportunity to network, discover new insights, and be part of the conversation shaping the future of cancer therapeutics. We look forward to meeting you in Barcelona! #ENA2024 #AACR #EORTCNCIAACR #CANCER #THERAPEUTICS #TARGETS

Kymera Therapeutics is making significant advancements with its IRAK4 degrader, KT-474, which is currently in Phase II clinical trials. The drug is being developed for the treatment of hidradenitis suppurativa and atopic dermatitis. In earlier Phase 1 trials, KT-474 demonstrated significant IRAK4 protein degradation - achieving up to 95% degradation in healthy volunteers, indicating its strong potential in treating complex inflammatory diseases. ICE Bioscience is at the forefront of supporting IRAK4-targeted therapeutic development. Our latest Application Note covers comprehensive assays for characterizing IRAK4 inhibitors and degraders. Learn more about how our capabilities can help accelerate your IRAK4 research! 👉 https://lnkd.in/gaczDuPr #IRAK4 #DrugDevelopment #Immunology #PROTAC #degraders #InnateImmunity #Inflammation #Biotech #Innovation

It's an exciting week of back-to-back conferences, and we continue the momentum at the SABPA 22nd San Diego BioPharma Conference! Thrilled to connect with industry and academic experts discussing the latest breakthroughs in BioPharma. Check out our live photos from the event! 📸 #SABPA #BIOPHARMA #BIOTECH #drugdiscovery #connection

Just wrapped up an amazing four days at the Discovery On Target 2024! We delivered 2 podium presentations and showcased 3 posters covering a range of targets from kinases to DDR targets and GPCRs, exploring from inhibitors to degraders and molecular glues. The discussions were vibrant and insightful, sparking new ideas and collaborations. We’re excited to see where these conversations lead us in the future! Looking forward to reconnecting at DOT 2025! #BostonDoT24 #DOT2024 #kinases #GPCRs #DDR #inhibitors #degraders #TPD

The ICE team had an energetic day at Discovery on Target! 🎉 We had a great time meeting everyone at booth **309** and connecting over some fantastic discussions. TJ Bing's talk on how our Biology Building Block Platform aids hit identification for oncology targets was a highlight, as well as Dr. Cong Huang’s insights on DNA damage response and synthetic lethality during the poster session. Excitingly, TJ Bing has also been invited to present a short talk during the GPCR session on **Thursday at 11:05 AM**. Don’t miss out—see you there! #DOT2024 #drugdiscovery #GPCR #TeamICE #CancerResearch #DDR #BostonDoT24 #target

ICE Bioscience is gearing up for BioJapan 2024! Join us at booth D-25 from October 9 to 11, 2024, at PACIFICO Yokohama. Get ready to dive into the latest in biotechnology, connect with industry innovators, and discover how we’re pushing the boundaries of drug discovery. Don’t miss out on this fantastic opportunity to explore, network, and be inspired! ICE BioscienceはBioJapan 2024に参加します！🎉 2024年10月9日から11日まで、横浜パシフィコのブースD-25にお越しください。 バイオテクノロジーの最新情報に触れ、業界の革新者とつながり、私たちが創薬の限界を押し広げている様子を発見してください。この素晴らしい機会をお見逃しなく！ #biojapan #drugdiscovery #CRO #exhibit #network #biotech #biopharma

In celebration of China’s National Day, our facilities in China will be closed from October 1 to October 7. To accommodate compound deliveries during this period, our Compound Management Team will accept shipments on October 1 and October 6. We appreciate your understanding during this holiday period and remain committed to providing you with exceptional service. If you have any questions or need further assistance, please don't hesitate to reach out. Thank you! #NationalDay #CompoundManagement #CustomerService

🏸 Last weekend, we had an amazing time at the ICE Cup Badminton Tournament! Our teams battled it out in men's singles, women's singles, and mixed doubles, showcasing their skills and sportsmanship. Check out the action-packed photos of everyone giving it their all on the court! The top 10 players will represent us in upcoming external competitions, and we couldn't be prouder! Let's keep the spirit alive and cheer them on! #ICEBioscience #BadmintonTournament #TeamSpirit #Sportsmanship